The CD19-ADC loncastuximab tesirine and coltuximab ravtansine (SAR3419) exhibited strong anti-tumoral effects in hematological malignancies in vitro and an acceptable safety profile in patients but only modest efficacy in relapsed/refractory BCP-ALL [14,58]. The gene discussed is CD19; the disease is hematologic disorder.